


Pharmaceutical Pricing and Reimbursement Policies in Singapore's Healthcare System

Ivan KOH Yu Fan¹, HO Yan Teck¹, Liang LIN¹, Kwong NG¹

¹Agency for Care Effectiveness (ACE), Ministry of Health (moh_dac_secretariat@moh.gov.sg)

The Agency for Care Effectiveness (ACE) is empowered by the Government of the Republic of Singapore, as its national health technology assessment (HTA) agency, to negotiate prices for patented drugs for funding under the Ministry of Health (MOH)'s List of Subsidised Drugs or Cancer Drug List. There are no statutory obligations regulating pharmaceutical pricing in Singapore.

Population: 5.9M
GDPPC: USD 84.8K
Healthcare expenditure:
~4% GDP



Price for national funding vs price for supply to healthcare institutions

- ACE's negotiations determine the maximum price pharmaceutical companies can sell a funded drug to healthcare providers.
- National tendering of both funded and non-funded drugs for national supply contracts by Singapore's national procurement agency provides opportunity to derive further cost savings.